Joseph Moryousef

Joseph Moryousef

Auto-generated profile, based on publicly available information

Joseph Moryousef

Department of Surgery, Division of Urology, McMaster University, Hamilton, Canada

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 January 2022 in The World Journal of Men's Health
Verified
Journal Article
Open access
PDF file
JOJesse Ory
Jesse Ory
MTMichael B. Tradewell
Michael B. Tradewell
UBUdi Blankstein
Udi Blankstein
TLThiago F. Lima
Thiago F. Lima
SNSirpi Nackeeran
Sirpi Nackeeran
Ranjith RamasamyRanjith Ramasamy
Ranjith Ramasamy
Ory J, et al. World J Mens Health. 2022 Jan;40:e14. https://doi.org/10.5534/wjmh.210159

1 January 2022 in Canadian Journal of Kidney Health and Disease
Verified
Journal Article
Open access
JMJoseph Moryousef
Joseph Moryousef
ÉBÉmilie Bortolussi-Courval
Émilie Bortolussi-Courval
TPTiina Podymow
Tiina Podymow
TLTodd C. Lee
Todd C. Lee
ETEmilie Trinh
Emilie Trinh
EMEmily G. McDonald
Emily G. McDonald
Background: End-stage kidney disease patients on dialysis have a substantial risk of polypharmacy due their propensity for comorbidity and contact with the health care system. MedSafer is an electronic decision support tool that integrates patient comorbidity and medication lists to generate personalized deprescribing reports focused on identifying potentially inappropriate medications (PIMs). Objective: To conduct a secondary analysis of patients on regular hemodialysis included in the MedSafer randomized controlled trial to investigate the patterns of polypharmacy and evaluate the efficacy of the MedSafer deprescribing algorithms. Design: Secondary analysis of a cluster randomized clinical trial. Setting: Medical units in 11 acute care hospitals in Canada. Patients: The MedSafer trial enrolled 5698 participants with an expected prognosis of >3 months, age 65 years and older, and on 5 or more daily home medications; 140 participants were receiving chronic hemodialysis. Measurements: The primary outcome of the trial was 30-day adverse drug events (ADEs) post-hospital discharge, and a key secondary outcome was deprescribing. Methods: Control patients received usual care (medication reconciliation), whereas clinicians caring for intervention patients received a MedSafer report that highlighted individualized opportunities for deprescribing. Results: There were 70 patients in each of the control and intervention arms. The median number of home medications was 14 (compared with a median of 10 medications in the general trial population). The most frequent medications observed that were potentially inappropriate were proton pump inhibitors (potentially inappropriate in 55/76 users; 72.4%), diabetes medications in patients with a HBA1C <7.5% (36/65 users; 55.4%), docusate (27/27 users; 100%), gabapentinoids (27/36 users; 75%), and combination antiplatelet/anticoagulants (22/97 users; 22.7%). The proportion of PIMs deprescribed was higher during the intervention phase (28.8% vs 19.3%; absolute increase 9.4% [95% confidence interval 1.3%-17.6%]) compared with the control phase. There was no observed difference in ADEs at 30-day post-discharge between the control and the intervention groups. The most common ADE (n = 3) was gastrointestinal bleeding attributed to antiplatelet agents. Limitations: This was a post hoc exploratory analysis, the original trial did not stratify by hemodialysis status, and the small sample size precludes drawing any definitive conclusions. Conclusion: MedSafer facilitates deprescribing in hospitalized patients on hemodialysis. Larger-scale implementation of decision support software for deprescribing in dialysis and long-term follow-up are likely required to demonstrate an impact on ADEs.

6 November 2024 in Prostate Cancer and Prostatic Diseases
Verified
Journal Article
Closed access
PDF file
JMJoseph Moryousef
Joseph Moryousef
WDWilhelmina Duivenvoorden
Wilhelmina Duivenvoorden
DLDarryl Leong
Darryl Leong
JPJehonathan H. Pinthus
Jehonathan H. Pinthus

29 November 2021 in Prostate Cancer and Prostatic Diseases
Verified
Journal Article
Closed access
PDF file
JMJoseph Moryousef
Joseph Moryousef
UBUdi Blankstein
Udi Blankstein
JNJ. Curtis Nickel
J. Curtis Nickel
YKYonah Krakowsky
Yonah Krakowsky
IGIan Gilron
Ian Gilron
KJKeith Jarvi
Keith Jarvi

26 June 2023 in Canadian Journal of Kidney Health and Disease
Verified
Journal Article
Open access
ÉBÉmilie Bortolussi-Courval
Émilie Bortolussi-Courval
TPTiina Podymow
Tiina Podymow
ETEmilie Trinh
Emilie Trinh
JMJoseph Moryousef
Joseph Moryousef
RHR. Hanula
R. Hanula
EMEmily Gibson McDonald
Emily Gibson McDonald
Background: Patients on dialysis are commonly prescribed multiple medications (polypharmacy), many of which are potentially inappropriate medications (PIMs). Potentially inappropriate medications are associated with an increased risk of falls, fractures, and hospitalization. MedSafer is an electronic tool that generates individualized, prioritized reports with deprescribing opportunities by cross-referencing patient health data and medications with guidelines for deprescribing. Objectives: Our primary aim was to increase deprescribing, as compared with usual care (medication reconciliation or MedRec), for outpatients receiving maintenance hemodialysis, through the provision of MedSafer deprescribing opportunity reports to the treating team and patient empowerment deprescribing brochures provided directly to the patients themselves. Design: This controlled, prospective, quality improvement study with a contemporary control builds on existing policy at the outpatient hemodialysis centers where biannual MedRecs are performed by the treating nephrologist and nursing team. Setting: The study takes place on 2 of the 3 outpatient hemodialysis units of the McGill University Health Centre in Montreal, Quebec, Canada. The intervention unit is the Lachine Hospital, and the control unit is the Montreal General Hospital. Patients: A closed cohort of outpatient hemodialysis patients visit one of the hemodialysis centers multiple times per week for their hemodialysis treatment. The initial cohort of the intervention unit includes 85 patients, whereas the control unit has 153 patients. Patients who are transplanted, hospitalized during their scheduled MedRec, or die before or during the MedRec will be excluded from the study. Measurements: We will compare rates of deprescribing between the control and intervention units following a single MedRec. On the intervention unit, MedRecs will be paired with MedSafer reports (the intervention), and on the control unit, MedRecs will take place without MedSafer reports (usual care). On the intervention unit, patients will also receive deprescribing patient empowerment brochures for select medication classes (gabapentinoids, proton-pump inhibitors, sedative hypnotics and opioids for chronic non-cancer pain). Physicians on the intervention unit will be interviewed post-MedRec to determine implementation barriers and facilitators. Methods: The primary outcome will be the proportion of patients with 1 or more PIMs deprescribed on the intervention unit, as compared with the control unit, following a biannual MedRec. This study will build on existing policies aimed at optimizing medication therapy in patients undergoing maintenance hemodialysis. The electronic deprescribing decision support tool, MedSafer, will be tested in a dialysis setting, where nephrologists are regularly in contact with patients. MedRecs are an interdisciplinary clinical activity performed biannually on the hemodialysis units (in the Spring and Fall), and within 1 week following discharge from any hospitalization. This study will take place in the Fall of 2022. Semi-structured interviews will be conducted among physicians on the intervention unit to determine barriers and facilitators to implementation of the MedSafer-supplemented MedRec process and analyzed according to grounded theory in qualitative research. Limitations: Deprescribing can be limited due to nephrologists’ time constraints, cognitive impairment of the hemodialyzed patient stemming from their illness and complex medication regimens, and lack of sufficient patient resources to learn about the medications they are taking and their potential harms. Conclusions: Electronic decision support can facilitate deprescribing for the clinical team by providing a nudge reminder, decreasing the time it takes to review and effectuate guideline recommendations, and by lowering the barrier of when and how to taper. Guidelines for deprescribing in the dialysis population have recently been published and incorporated into the MedSafer software. To our knowledge, this will be the first study to examine the efficacy of pairing these guidelines with MedRecs by leveraging electronic decision support in the outpatient dialysis population. Trial registration: This study was registered on Clinicaltrials.gov (NCT05585268) on October 2, 2022, prior to the enrolment of the first participant on October 3, 2022. The registration number is pending at the time of protocol submission.

3 March 2022 in Andrologia
Verified
Journal Article
Closed access
MAMohammad H. Alkandari
Mohammad H. Alkandari
JMJoseph Moryousef
Joseph Moryousef
AZArmand Zini
Armand Zini